Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masud Haq is active.

Publication


Featured researches published by Masud Haq.


Nuclear Medicine Communications | 2004

Thyroid cancer: an overview

Masud Haq; Clive Harmer

&NA;


Archive | 2006

Rare Thyroid Cancers

Masud Haq; Clive Harmer

cancer in general is due to the preponderance of well-differentiated carcinoma, a subset of rare thyroid tumors exist that exhibit aggressive behavior and poor prognosis. These require careful consideration and different treatment paradigms to optimize clinical outcome. Extremely rare types of thyroid cancer include thymus-like tumors, mucoepidermoid carcinoma, spindle cell tumor, mixed medullary follicular cancers, and teratoma. In view of the limited literature on their management these extremely rare types are not covered in this chapter.


World Journal of Surgical Oncology | 2008

Erratum to: Thyroid cancer causing obstruction of the great veins in the neck

Steve L Hyer; Prasad Dandekar; Kate Newbold; Masud Haq; Kshama Wechalakar; Khin Thway; Clive Harmer

Background and aims: To report our experience and review the literature of thyroid cancer obstructing the great veins in the neck, highlighting clinical aspects and response to treatment.


Nuclear Medicine Communications | 2004

Whole-body and blood dosimetry for radioiodine treatment of differentiated thyroid cancer

Masud Haq; Brenda Pratt; Glenn D. Flux; Clive Harmer

IntroductionIdeally, the administration of radioiodine (RAI) therapy for the treatment of differentiated thyroid cancer (DTC) would be carried out on a patient-specific basis. This requires individual dosimetry calculations. AimTo calculate whole-body absorbed doses (WBD) and blood doses (BD) resulting from different levels of administration, to determine whether a correlation exists between the levels of administered activity and these toxicity criteria. MethodsEighty-two patients underwent 110 treatments. Serial whole-body activity measurements were taken following administration of 3, 5.5 and 9 GBq RAI. Blood samples were taken at 48, 72 and 144 h for similar evaluations. WBD and BD were calculated using standard MIRD methodology with interpolated S values. ResultsWBD and BD values are expressed as mean±SD Gy. After 3 GBq, WBD=0.18±0.04, BD=0.31±0.08; after 5.5 GBq, WBD=0.34±0.14, BD=0.64±0.38; and after 9 GBq, WBD=0.66±0.39, BD=0.94±0.44. Whilst higher administered activities resulted in higher absorbed whole-body and blood doses, no adverse haematological toxicity was observed throughout the study. ConclusionThe determination of absorbed whole-body and blood doses can be used as a guide to the safe prescription of administered activity up to 9 GBq. These methods can help predict and minimize potential toxicity.


The Journal of Clinical Endocrinology and Metabolism | 2007

131I Activity for Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Systematic Review

Allan Hackshaw; Clive Harmer; Ujjal Mallick; Masud Haq; J. A. Franklyn


European Journal of Nuclear Medicine and Molecular Imaging | 2010

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer

Glenn D. Flux; Masud Haq; Sarah J. Chittenden; Susan Buckley; Cecilia Hindorf; Kate Newbold; Clive Harmer


World Journal of Surgical Oncology | 2008

Thyroid cancer causing obstruction of the great veins in the neck

Steve L Hyer; Prasad Dandekar; Kate Newbold; Masud Haq; Kshama Wechalakar; Clive Harmer


Nuclear Medicine Communications | 2004

Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy.

Masud Haq; Ralph V. Mccready; Clive Harmer


Archive | 2006

Non-surgical Management of Thyroid Cancer

Masud Haq; Clive Harmer


British Journal of Radiology | 2007

Differentiated thyroid cancer presenting with thyrotoxicosis due to functioning metastases

Masud Haq; S. Hyer; Glenn D. Flux; Gary Cook; Clive Harmer

Collaboration


Dive into the Masud Haq's collaboration.

Top Co-Authors

Avatar

Clive Harmer

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Kate Newbold

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Glenn D. Flux

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Kshama Wechalakar

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Prasad Dandekar

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Steve L Hyer

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Gary Cook

King's College London

View shared research outputs
Top Co-Authors

Avatar

Khin Thway

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Sarah J. Chittenden

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge